KRAS and neoplasm: PDAC has been shown to have multi-step molecular progression including high frequency of activating K-ras mutations and subsequent inactivation of p16INK4a, p53, SMAD4, p14ARF tumor suppressors and other additional genetic abnormalities in mouse models [4]–[6] and in human [7].